Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

NCT04225715 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04225715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04225715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Adaptive, Open-Label Platform Trial To Evaluate Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2020
Completion date
July 19, 2024
Enrollment
281 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, chronic